FilingReader Intelligence
Walvax Bio reports lower profit, sets dividend amid strategic shifts
April 11, 2025 at 05:55 PM UTC•By FilingReader AI
Walvax Biotechnology (SZSE:300142) reported a FY2024 net profit of CNY 142.16 million, a 66.10% decrease year-over-year, citing decreased domestic sales, lower market prices on key products, inventory write-offs, and organizational changes. The company announced a cash dividend of CNY 0.10 per 10 shares, allocating CNY 15.99 million for distribution.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement on Adjusting the Completion Time of Implementation of Raised Fund Investment ProjectsApril 11, 2025 at 11:51 AM UTC
Announcement on the Provision for Asset Impairment and Annual Write-off of Assets in the Fourth Quarter of 2024April 11, 2025 at 11:51 AM UTC
Announcement on applying for a credit line for M&A loans from financial institutionsApril 11, 2025 at 11:51 AM UTC
Announcement on the 2024 Profit Distribution PlanApril 11, 2025 at 11:51 AM UTC
2024 Annual Audit ReportApril 11, 2025 at 11:51 AM UTC
2024 Annual Report of the Board of DirectorsApril 11, 2025 at 11:51 AM UTC
2024 Internal Control Evaluation ReportApril 11, 2025 at 12:05 PM UTC
Notice on the convening of the 2024 Annual General Meeting of ShareholdersApril 11, 2025 at 12:05 PM UTC
2024 Annual Report SummaryApril 11, 2025 at 12:05 PM UTC
2024 Annual Financial ReportApril 11, 2025 at 12:05 PM UTC
2024 Annual ReportApril 11, 2025 at 12:05 PM UTC
News Alerts
Get instant email alerts when Walvax Biotechnology publishes news
Free account required • Unsubscribe anytime